Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

PharmAthene Inc (NYSE MKT LLC:PIP)

1.69
Delayed Data
As of Jul 31
 0.00 / 0.00%
Today’s Change
1.25
Today|||52-Week Range
2.59
-6.63%
Year-to-Date
SECTOR
Commercial Services
INDUSTRY
Miscellaneous Commercial Services
MARKET CAP
$107.8M

Company Description

PharmAthene, Inc. operates as a biodefense company, which is engaged in the development and commercialization of medical countermeasures against biological and chemical threats. Its biodefense candidates include Anthrax vaccines including SparVax, a second generation liquid recombinant protective antigen, anthrax vaccine and a next generation lyophilized anthrax vaccine containing rPA; recombinant butyrylcholinesteras bioscavenger, a medical counter measure for nerve agent poisoning by organ phosphorous compounds, including nerve gases and pesticides; and valortim, a fully human monoclonal antibody for the prevention and treatment of anthrax infection. The company was founded in March 2001 and is headquartered in Annapolis, MD.

Contact Information

PharmAthene, Inc.
1 Park Place
Annapolis Maryland 21401
P:(410) 269-2600
Investor Relations:

Employees

Shareholders

Individual stakeholders36.23%
Mutual fund holders3.65%
Other institutional27.31%

Top Executives

John M. GillPresident, Chief Executive Officer & Director
Jeffrey Michael JonesChief Operating Officer & Vice President
Philip MacNeillCFO, Secretary, Treasurer & Vice President